Opinion|Videos|January 15, 2025
Adverse Event Management and Emerging Therapies in Ovarian Cancer: PARPi Challenges and the Role of ADCs
Author(s)Thomas J. Herzog, MD, John Chan, MD
Panelists discuss the most common adverse events associated with PARP inhibitor (PARPi) therapy in ovarian cancer and strategies for mitigating or managing these adverse effects. They also review recent data on antibody-drug conjugates (ADCs) in ovarian cancer, including the evolving role of mirvetuximab soravtansine in the FORWARD II trial, and other ADCs such as luveltamab tazevibulin and rinatabart sesutecan, highlighting promising findings from studies presented at ESMO 2024. The session concludes with a discussion on future perspectives in ovarian cancer treatment, offering insights into emerging therapies and the evolving landscape.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Dr Chan to Dr Herzog: What adverse events are most seen with PARPi therapy, and how do you mitigate or manage these?
- Dr Herzog: Briefly comment on recent data surrounding ADCs in ovarian cancer and discuss the evolving role of these agents in the treatment landscape.
- Dr Herzog to address: Mirvetuximab soravtansine (anti-FR)
- FORWARD II (
Gynecol Oncol. 2024 MIRASOL) (N Engl J Med. 2023 ;ASCO 2024 abstract 5582 ) - Dr Chan to address: Luveltamab tazevibulin (anti-FR), Rinatabart sesutecan (Rina-S)
- Rinatabart sesutecan (Rina-S) -
Lee EK, et al. ESMO 2024. Abs 719MO - STRO-002-GM1 (
Pothuri, et al. ESMO 2023. Abstract 741MO )
- All faculty: Please share future perspectives and closing thoughts on the treatment of ovarian cancer.
Advertisement
Related to this article
The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.
Pankit Vachhani, MD, discusses the importance of hematocrit control in the management of polycythemia vera.
Pembrolizumab plus denosumab produced a 31% ORR and 53% 6-month PFS rate in VEGFR-TKI-pretreated advanced clear cell renal cell carcinoma.
A new study suggests genomic newborn screening could identify children at risk for early cancers and enable earlier diagnosis and less toxic treatment.
The CLDN18.2/CD47 bispecific antibody spevatamig has received FDA fast track designation for advanced and metastatic biliary tract carcinoma.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Hamza Hashmi, MD, discusses the evolving role and implementation of CAR T-cell therapy in early relapsed/refractory multiple myeloma.
The HER2-directed ADC produced confirmed responses across both biomarker-defined cohorts of advanced salivary gland carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
3
Novel Approaches for Hematocrit Control Are Driving Research in Polycythemia Vera
4
Dr Viansone on De-Escalating Chemotherapy Type and Duration in HER2-Positive Breast Cancer
5